![](https://potportal.net/wp-content/uploads/2024/07/1_ywOjWaarN2PbE9_lEonPgQ.jpg)
A new report from New York State’s Office of Cannabis Management (OCM) reveals that more than 75% of medical marijuana patients in the state have reduced their intake of prescription drugs due to cannabis use. Notably, 66% of these patients reported a specific reduction in their need for prescription opioids for pain management.
The comprehensive 40-page report draws on surveys conducted last year with current and former medical marijuana patients, as well as medical providers who recommend cannabis. The document covers a range of topics, including qualifying conditions, frequency of use, product types, and patient demographics. It also offers recommendations for enhancing New York’s medical cannabis system.
Despite some challenges, the report indicates general satisfaction among participants in the medical marijuana program. Seventy-nine percent of patients plan to renew their certifications upon expiration, and 86% would recommend the program to friends or family.
To improve the system, the report suggests several measures, including:
– Extending patient certifications from one year to two years.
– Repealing the tax on medical cannabis.
– Allowing patients and caregivers to possess either the Penal Law limits or a 60-day supply of medical cannabis, whichever is greater.
– Removing the two-hour course requirement for providers, allowing the Board to determine necessary training.
– Enacting patient reciprocity to enable out-of-state medical cannabis patients to purchase products in New York.
– Allowing certified patients and caregivers aged 18 and older to cultivate medical cannabis for personal use.
– Requiring coursework on the endocannabinoid system and medical cannabis at NYS higher education institutions, including medical schools.
– Developing policies for faculty at NYS higher education institutions to conduct cannabis research with a NYS Cannabis Research License.
– Supporting insurance companies in covering medical cannabis products.
– Implementing Continuing Medical Education (CME) requirements on medical cannabis for all licensed providers in NYS.
– Continuing to require onsite pharmacists at all medical cannabis dispensaries.
The report highlights that pain management is a primary reason for cannabis use among patients. Sixteen percent of patients use it as an opioid alternative for pain that degrades health and functional capability, and 80% of patients certified under the “other” category have chronic pain alongside another condition. Healthcare providers also noted cannabis’s benefits, with 95% finding it helpful for reducing or treating pain, and 84% indicating improvements in patients’ overall physical functioning.
This report mirrors findings from similar studies, such as a recent review of Ohio’s medical marijuana program, which found that a large majority of patients reported reducing their use of prescription opioids and other drugs due to cannabis.
Overall, the report underscores the positive impact of medical cannabis on reducing reliance on prescription medications, particularly opioids, and offers a roadmap for improving the program to better serve New York’s medical marijuana patients.
Read the whole article here.